Journal of Dermatology Research’s Post

🌟 Rare Disease Spotlight: Interstitial Granulomatous Dermatitis📚 A rare skin disorder in which there is a particular pattern of granulomatous inflammation. 🔔 The features of interstitial granulomatous dermatitis are variable. ◼ Red or skin-coloured patches, papules and plaques ◼ The shape of the lesions may be round, annular or cord-like. ◼ Lesions wax and wane, and may vary in size and shape over days to months. ◼ They are usually symptomless, but some patients complain of mild itch or burning sensation. ◼ The lesions tend to be symmetrically distributed on the trunk, but proximal limbs may also be affected. ◼ It most commonly affects middle-aged women. ◼ Many affected patients also suffer from autoimmune disease. 📌 Interstitial granulomatous dermatitis is diagnosed by a pathologist on examining a skin biopsy. The characteristic histological features of interstitial granulomatous dermatitis are: ✔ Dense histiocytic inflammation in the reticular (lower) dermis ✔ Sparse neutrophils and eosinophils ✔ Perivascular and interstitial lymphocytes ✔ Interstitial histiocytes (between the collagen bundles) or palisaded histiocytes (lined up perpendicular to fragmented central collagen). ✔ Focal degeneration of collagen, which may be surrounded by space (floating sign) ✔ Few giant cells. #Dermatology #SkinHealth #MedicalResearch #IGD #DermatologicConditions #HealthcareInnovation

Check out the NACE Webcast: Atopic Dermatitis: Evaluation and Targeted Management. Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions located on flexural surfaces. The itch that accompanies AD has a significant impact on patients’ quality of life, with the most prominent impact being on sleep quality. Fortunately, a new understanding of its underlying pathophysiology has brought about a variety of effective treatment options for patients suffering from AD, from topical agents to biologics and oral Janus kinase (JAK) inhibitors. In this webcast, Mona Shahriari, MD, FAAD, will share her valuable insights on differential diagnosis, treatment goals, and individualizing treatment plans. Click here to start the course: https://bit.ly/3WdObsm #NACE #Dermatology #Webcast

Did you know that there is no cure for hidradenitis suppurativa (HS)? The exact cause of the disease is unknown, but the lumps develop because of blocked hair follicles, making HS often looking like pimples or boils. It is a progressive disease in the sense that severity of the disease typically worsens over time. At UNION, we are committed developing safe and effective medicines that can help improve quality of life among patients suffering from immunological diseases including HS. We have spoken to Sara, diagnosed with HS, a chronic progressive inflammatory skin disease, to get an understanding of her everyday live with HS. #hidradenititssuppurativa #hs #orismilast #union #dermatology #pde4 #immunology

Under the motto “Uncovering the Broad Spectrum of Psoriatic Disease” the 7th World Psoriasis & Psoriatic Arthritis Conference took place last week in Stockholm. The focus of the conference is to improve the lives of patients living with psoriatic disease by sharing significant achievements in the prevention, diagnosis, and treatment. With PsorX-LabDisk, we support dermatopathologists in the differential diagnosis of psoriasis and eczema - as there are still up to 50% misdiagnoses of the two skin diseases due to overlapping clinical and histological appearances. However, the feedback from the dermatologists at the conference was clear: ❗This is not enough❗The test needs to be introduced into dermatologists' practices for use at the point of care. How good that work on it is already in full swing in the Dermagnostix R&D team!💪🚀 This feedback once again reinforces our belief in the urgent need for molecular diagnostics for inflammatory skin diseases - both for dermatologists and pathologists. 💡You want to be part of the #DermagnosticFuture? Schedule a meeting with us now to learn more about PsorX: https://lnkd.in/egn75BGc #MolecularDiagnostics #Psoriasis #PsorX #Dermatology #Innovation #IFPA

Today, thanks to advances in #medicalscience, we know that prurigo nodularis (PN) involves a complex interplay between the immune and nervous systems, leading to severe and pathological itching. In an exciting #dermatology development, the @FDA has just approved the breakthrough treatment Nemluvio® (nemolizumab-ilto), which targets Interleukin (IL)-31, a key neuroimmune cytokine involved in the severe itching, inflammation, and fibrosis seen in PN. Nemolizumab, a humanized IgG2 monoclonal antibody, works by inhibiting IL-31 signaling. Its approval is backed by data from two successful Phase 3 #clinicaltrials: OLYMPIA 1 and OLYMPIA 2, involving 560 patients. Results showed a significant reduction in itch intensity and #skin clearance for many patients, marking a huge step forward in managing this challenging condition. Key Efficacy Results: OLYMPIA 1: 22% of patients on nemolizumab saw at least a 4-point reduction in itch intensity, compared to just 2% in the placebo group. OLYMPIA 2: 25% of patients on nemolizumab experienced similar improvements versus 4% on placebo. Advancements like these highlight the importance of continued #dermatologyresearch in the connection between the immune system and chronic conditions. This is an exciting development for #healthcare providers and patients alike, offering new hope for managing prurigo nodularis. #Dermatology #FrontierDermatology #FDAApproval #Nemluvio #Nemolizumab #PrurigoNodularis #Dermatology #HealthcareInnovation #SkinCondition #HealthySkin #SkinHealth #BetterSkin #SkinGlow #GlowingSkin #SkinGoals https://lnkd.in/gtv_QWrM

Imagine integrating genetic testing and a comprehensive drug efficacy panel into your treatment plans. 🧬 Imagine detailed reports with recommended compounds based on efficacy levels. 💊 Imagine the transformative impact on your treatment outcomes. 🚀 Join our webinar to learn about this revolutionary approach through clinical cases. 🌟 #genetictesting #personalizedmedicine

We had such wonderful, constructive conversations again at the symposium of the general membership meeting of V&VN Wondexpertise on March 7 (NL). Plasmacure gave a presentation about PLASOMA cold plasma therapy to share knowledge with the experts about this innovative treatment method for wound healing.   Cold plasma stimulates wound healing. Using PLASOMA, a cold plasma pad is applied over the wound bed. Electricity is added to the trapped ambient air under the pad. As a result it turns into a gas with disinfectant and healing properties. This gas is called cold plasma.   The great thing about PLASOMA is that it produces cold plasma directly in the wound bed, in a closed system. Many listeners did not yet know the benefits and found it interesting to hear that cold plasma kills bacteria, including antibiotic-resistant ones, inactivates biofilm, stimulates cell proliferation and improves microcirculation.   Quick and easy to use, that is central to the use of PLASOMA to stimulate healing of wounds that show delayed healing.   Do you want to learn more about this treatment method? Visit our website: https://lnkd.in/esahs4wb   #woundcare #diabeticfoot #infection #woundhealing #biofilm #dermatology #chronicwounds #diabetes #burns #skin #surgery #coldplasma #easme #medtech #medical #medicaldevice #plasma #wounds #ulcer #vascularsurgery #PLASOMA #plasmatechnology  #AMR #amputationprevention

Psoriasis is a chronic inflammatory skin condition characterized by excessive keratinocyte growth and immune cell infiltration. Although the exact causes are still not fully understood, recent research suggests that iron imbalance may contribute to the disease. Remarkably, research dating back as far as fifty years has shown elevated iron levels in the epidermis of patients with psoriasis.  In a recent study published in Nature Communications by Nature Portfolio, scientists focused on hepcidin, a hormone that regulates iron levels in the body. Using in vitro 3D skin cultures and in vivo mouse models, the research team established a key role for hepcidin in initiating skin inflammation in psoriasis. As hepcidin regulates iron levels and inflammation, modulating its activity may help manage chronic inflammation in patients with psoriasis. Psoriasis remains difficult to treat, and this study opens new avenues for exploring hepcidin as an actionable target for psoriasis management. We are proud that our product could assist in this discovery and contribute to advancing potential treatments for psoriasis. Abboud, E., Chrayteh, D., Boussetta, N. et al. Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment. Nat Commun 15, 6718 (2024). https://lnkd.in/gGzENa_S Elise Abboud, PhD #cellculture #skinresearch #dermatology

Just published on the Journal of Dermatological Treatment! "Clinical course and disease burden of patients with generalized pustular psoriasis in Portugal: a multicenter retrospective cohort study". In this multicenter study, coordinated by the Portuguese Group of Psoriasis, we evaluated the clinical characteristics, triggering factors, morbidity, disease progression and treatment response in patients diagnosed with GPP in Portugal. Our analysis highlights the chronic, heterogeneous, and debilitating nature of GPP, associated with multiple flares, leading to hospitalizations and emergency department visits, significantly compromising the quality of life and survival of patients. Moreover, standard treatment options often fail to achieve adequate disease control. #GPP #Dermatology #Portugal

Don't miss this opportunity to revolutionize your approach to alopecia treatment. REGISTER NOW to secure your place and embark on a transformative journey to better patient care. Places are limited, so act fast! We look forward to seeing you there! #TrichoTest #PersonalizedMedicine #GeneticTesting #AlopeciaTreatment #HairLossCare #Dermatology #Webinar #ClinicalPractice